Abbott’s Omacor For Triglyceride Level Reduction Clears FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
The omega-3-acid ethyl esters product is indicated as an adjunct to diet in the reduction of “very high” triglyceride levels. Solvay markets Omacor in Europe; Reliant is expected to market Omacor in the U.S.
You may also be interested in...
Reliant's Antara Launch Set For First Quarter, Omacor Will Be Later
The cholesterol products have the potential to transform the company by generating annual sales of $150 mil. each, CEO Ernest Mario says. Reliant is considering possible combinations for Omacor; options include Antara or a statin.
Reliant's Antara Launch Set For First Quarter, Omacor Will Be Later
The cholesterol products have the potential to transform the company by generating annual sales of $150 mil. each, CEO Ernest Mario says. Reliant is considering possible combinations for Omacor; options include Antara or a statin.
Reliant Will Launch Pronova's Omacor In 2005
Reliant will maintain the NDA for Omacor (omega-3 acid ethyl esters) and its sales force will be the sole U.S. marketer of the hypertriglyceridemia treatment. Abbott's Ross Products division filed the original NDA, as well as a separate application FDA has deemed "approvable."